Sinphar Pharmaceutical Co. Ltd. AI Stock Analysis
Sinphar Pharmaceutical Co. Ltd. (1734) AI Stock Analysis
Sinphar Pharmaceutical Co. Ltd.
(TWSE:1734)
Sinphar earns an above-average score driven primarily by solid and improving fundamentals: four consecutive years of profit growth, consistent margin expansion, meaningful debt reduction to a conservative 0.44 debt-to-equity, and a shift from cash burn to healthy free cash flow. Valuation is supportive, with a moderate 16.1x P/E and a 3.16% dividend yield. The main drag is the technical setup, where the stock has fallen below its key short- and medium-term moving averages with negative MACD and deeply oversold momentum readings. Secondary concerns include a 10.6% ROE, a flat asset base suggesting limited expansion, and historically uneven free cash flow, which together cap the score despite the fundamental improvement.
Sinphar Pharmaceutical Co. Ltd. (1734) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 6.05B
- Dividend Yield
- 3.13%
- Average Volume (3M)
- 206.55K
- Price to Earnings (P/E)
- 16.2
- Beta (1Y)
- 0.14
- Revenue Growth
- 2.44%
- EPS Growth
- -3.96%
- Country
- TW
- Employees
- 1,829
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Pharmaceuticals
Sinphar Pharmaceutical Co. Ltd. Business Overview & Revenue Model
Company Description
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesi...
Sinphar Pharmaceutical Co. Ltd. Financial Statement Overview
Summary
Sinphar has executed a credible turnaround: revenue has grown from NT$2.39B to NT$3.37B with gross margin expanding every year to 43.2% and operating margin recovering to 12.9% from losses. The balance sheet is the strongest in five years, with debt cut to NT$1.51B and debt-to-equity down to 0.44, while equity funds about 56% of assets. Cash generation has also improved sharply, with operating cash flow of NT$584.7M and free cash flow of NT$383.7M. Offsetting these strengths are modest absolute returns (10.6% ROE), a flat asset base implying limited expansion, earnings partly flattered by non-operating items, and historically volatile free cash flow that dipped negative as recently as 2023.
Income Statement
72PositiveBalance Sheet
70PositiveCash Flow
68Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.45B | 3.37B | 3.15B | 2.96B | 2.86B | 2.43B |
| Gross Profit | 1.52B | 1.46B | 1.24B | 1.09B | 1.09B | 888.71M |
| EBITDA | 687.37M | 689.70M | 601.24M | 582.94M | 539.57M | 109.64M |
| Net Income | 351.67M | 365.75M | 304.70M | 375.17M | 224.64M | -38.13M |
Balance Sheet | ||||||
| Total Assets | 6.84B | 6.15B | 6.30B | 6.25B | 6.19B | 6.22B |
| Cash, Cash Equivalents and Short-Term Investments | 1.60B | 994.63M | 1.18B | 1.08B | 1.24B | 1.24B |
| Total Debt | 2.05B | 1.51B | 1.90B | 1.95B | 1.91B | 2.13B |
| Total Liabilities | 3.12B | 2.44B | 2.75B | 2.85B | 2.97B | 3.14B |
| Stockholders Equity | 3.45B | 3.44B | 3.26B | 3.10B | 2.93B | 2.72B |
Cash Flow | ||||||
| Free Cash Flow | 326.35M | 383.72M | 336.80M | -4.57M | 271.85M | -25.90M |
| Operating Cash Flow | 598.46M | 584.66M | 593.51M | 296.37M | 425.30M | 135.54M |
| Investing Cash Flow | -259.92M | -224.63M | -391.08M | -334.56M | -124.24M | -205.60M |
| Financing Cash Flow | 195.09M | -576.03M | -209.08M | -106.84M | -263.32M | 122.95M |
Sinphar Pharmaceutical Co. Ltd. Peers Comparison
Overall Rating
TW:416670Outperform
TW:474664Neutral- TW:173464Neutral
TW:416760Neutral
TW:411948Neutral
TW:179945Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4166 | 70Outperform | TWD 5.47B | 22.88 | ― | ― | ― | ― |
| TW:4746 | 64Neutral | TWD 5.43B | 11.40 | ― | 6.64% | -2.71% | ― |
| TW:1734 | 64Neutral | TWD 6.07B | 16.18 | ― | 3.13% | 2.44% | -3.96% |
| TW:4167 | 60Neutral | TWD 6.30B | 6.34 | ― | 4.23% | -0.05% | 64.82% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4119 | 48Neutral | TWD 5.85B | 96.18 | ― | 1.53% | -18.83% | -87.54% |
| TW:1799 | 45Neutral | TWD 6.24B | -192.69 | ― | ― | 59.53% | 83.16% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:1734 | Sinphar Pharmaceutical Co. Ltd. | 30.15 | 1.76 | 6.19% | |
| TW:1799 | Easywell Biomedicals, Inc. | 24.55 | -9.10 | -27.04% | |
| TW:4119 | SCI Pharmtech Corp. | 48.50 | -0.61 | -1.25% | |
| TW:4166 | Orient Pharma Co., Ltd. | 22.55 | -2.05 | -8.33% | |
| TW:4167 | Savior Lifetec Corp. | 19.25 | 2.48 | 14.77% | |
| TW:4746 | Formosa Laboratories, Inc. | 45.40 | -15.89 | -25.92% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026